Syndesis Health
NEW YORK, NY / ACCESSWIRE / May 11, 2023 / Syndesis Health announced today that it has signed a research collaboration and information sharing agreement with Fundación Cardio Infantil Instituto de Cardiología (LaCardio), a leading cardiovascular hospital in Bogotá, Colombia.
LaCardio is joining the Syndesis Health Network alongside progressive healthcare institutions from South America, Asia, and Africa. Syndesis Health created its global network of healthcare partners to enable secure access to a multi-country, real-world data set. Syndesis Health's global research platform, Syntium, unifies de-identified clinical data from these healthcare partners in a secure, ethical, and compliant manner for the improvement of global health outcomes.
The partnership enables LaCardio to extend its commitment to improving patient outcomes by leveraging the Syndesis Health platform for access to data, analytics, and other technical resources. In addition, the partnership enables the hospital to engage in collaborative research opportunities with peer institutions around the world that are a part of the network.
Hans Godfrey, COO and head of Latin America data partnerships for Syndesis Health, commented: "We believe that the future of healthcare will be data-driven. With LaCardio as a partner in the Syndesis Health Network, we will together expand the potential for real-world data to enable research and treatments in the cardiovascular space."
Dr. Juan Gabriel Cendales, Executive Director of LaCardio, stated: "One of the strategic priorities of LaCardio as a university hospital and scientific research center is to continue advancing in scientific studies while contributing to the health of the people in Colombia and the region. Having valuable data, evaluating, and applying tools, such as AI, in healthcare allows us to anticipate the needs of the population, evaluate new alternatives and improve the experience of patients and collaborators. This alliance is part of the path in which we are working to be the hospital of the future."
About Syndesis Health
Syndesis Health accelerates research and innovation for healthcare and life sciences companies. The company was founded on the potential for real-world clinical data to advance medical research, improve patient health outcomes, and inform healthcare policy decisions. The Syndesis Health Network enables secure collaboration amongst member organizations and is powered by Syntium, the Syndesis data platform. Visit our website at https://syndesis.com to learn more.
About LaCardio
Fundación Cardioinfantil-LaCardio is a private, nonprofit institution with 50 years of experience. Founded in 1973 by brothers Reinaldo and Camilo Cabrera Polanía, it is one of the few Colombian institutions accredited by the Joint Commission International and has national accreditation granted by ICONTEC. Since 2015, LaCardio is recognized as a University Hospital by the Intersectoral Committee for Human Talent in Health, in compliance of the Ministries of Health and Education of Colombia. Its commitment to health transcends through its mission: to operate on low-income children with heart problems. The MERCO 2022 ranking positioned LaCardio as the best hospital in Colombia. In 2021, Americaeconomia ranked LaCardio 5th in Latin America, evaluating key processes and indicators, including patient safety & dignity, human capital, capacity, and knowledge management.
Contact Information
Leah Patterson
Chief Marketing Officer
leah.patterson@syndesis.com
+1.646.274.1420
Liliana Milena Toro Sánchez Sánchez
Marketing & Communications
lmtoro@lacardio.org
+3157288712
SOURCE: Syndesis Health
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/754175/Syndesis-Health-LaCardio-Sign-Research-Collaboration-Agreement
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Announces 2026 Strategic Objectives in Historically Strong PGE and Copper Markets13.1.2026 01:10:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / January 12, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU0(OTCQB:CLRMF) is pleased to provide an overview of its 2026 objectives and highlights of 2025, for its 100%-owned Thunder Bay North ("TBN") Critical Minerals Project in Northwestern Ontario. Critical Project Advancement Objectives Spot prices for platinum, copper and palladium have appreciated by 70% (1000 $/oz), 25% (1.20 $/lb) and 50% 624($/oz) respectively versus study prices, since the results of the Preliminary Economic Assessment (PEA) were announced in the October 9th release. Using the financial model published in the PEA and applying current spot metal prices (as of January 6th), the TBN project shows a $708M1 NPV8 and a pre-tax IRR of 100% (post-tax NPV8 = $494M1 and IRR = 84%).This is a significant improvement in the project outlook in comparison to the PEA results that featured a $219.4M2 pre-tax NPV8 and a pre-tax IRR of 39%. This year, cons
Germany Buys Eight MQ-9B SeaGuardian(R) RPA Through NSPA12.1.2026 20:00:00 CET | Press release
NSPA Supports NATO Countries in the Acquisition and Sustainment of GA-ASI's Advanced Multi-Domain RPA SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 12, 2026 / Germany's Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support and the NATO Support and Procurement Agency (NSPA) have announced the procurement of eight MQ-9B SeaGuardian® Remotely Piloted Aircraft (RPA) from General Atomics Aeronautical Systems, Inc. (GA-ASI). The program includes four Certifiable Ground Control Stations. First delivery is expected in 2028. Germany joins a growing list of NATO countries that have selected GA-ASI's advanced MQ-9B RPA for its multi-domain capabilities with exceptionally long range and endurance. The platform provides pole-to-pole satellite control and de-icing capabilities to enable missions in cold climates. SeaGuardian features two multi-mode surface-search radars that deliver wide-area maritime surveillance, with an option to add Anti-Submarine Warfare capa
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom